We use analytics and advertising cookies, which you can accept or reject; see our privacy policy.

Current choice:

Fig. 1 · Structure
Cat. No.
A10576
CAS No.
60-56-0
Formula
C4H6N2S
Mol. Weight
114.17

Documents & Downloads

Methimazole

Anti-thyroid Agent

Methimazole is an anti-thyroid agent that inhibits the synthesis of thyroid hormones in the thyroid gland by blocking the enzyme thyroid peroxidase. This reduction in hormone production is critical for managing hyperthyroidism and other related conditions. It is important to note that methimazole may pose a risk of hepatotoxicity, necessitating careful monitoring during use in research applications.

In Stock

Notify me when the price drops

For laboratory research use only. We do not sell to patients.

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

In Vitro Studies

Methimazole was added to human heart microsome incubation mixtures before verapamil addition. Verapamil metabolite formation was only slightly decreased compared with incubations containing no inhibitor. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Methimazole and Verapamil Metabolite Formation in Human Heart Microsomes

Cell-based study · human heart microsomes [1]

Methimazole was added to incubation mixtures containing human heart microsomes before verapamil addition. Methimazole only slightly decreased verapamil metabolite formation compared with incubations containing no inhibitor.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Formation rates of verapamil metabolitesReported result methimazole 200 µM; verapamil (400 µM): only slightly decreased the formation of verapamil metabolites.[1]

Literature-Reported Treatment Conditions

Treatment concentration
200 µM
Exposure duration
warmed at 37°C for 10 minutes prior to the addition of verapamil (400 µM)
Method
added to incubation mixtures containing human heart microsomes
Reported limits
Not stated in the sentences used: vehicle.
Methods and source locations

Compound reported in the paper: Methimazole

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Results > CYP450 activities in human heart microsomes > Verapamil metabolism in human heart microsomes (S28); Materials and Methods > CYP450 activities in human heart microsomes > In vitro incubations (S93); Materials and Methods > CYP450 activities in human heart microsomes > Inhibition studies (S101, S103, S104)

Formation rates of verapamil metabolites: Formation rates of verapamil metabolites; comparator: incubations containing no inhibitor — Results > CYP450 activities in human heart microsomes > Verapamil metabolism in human heart microsomes (S28); Materials and Methods > CYP450 activities in human heart microsomes > Inhibition studies (S101, S103, S104)

In Vivo Studies

In mice receiving Methimazole intraperitoneally, freezing increased during the latter ‘post-tone’ period but not during the early ‘pre-tone’ period, without shock or tone delivery. Substantial weight loss was also observed in mice weighed daily after Methimazole injection. [2]

Methimazole and Freezing Behaviour in Mice

Animal study · Mice [2]

Mice were injected intraperitoneally with 75 mg/kg of methimazole (Sigma) in sterile saline or an equivalent volume of saline. Without any shock or tone delivery: an increase in freezing levels during the latter part of the behavioural sessions, referred to as ‘post-tone’ period, but not during the early ‘pre-tone’ period. The observed immobility is, therefore, likely to be non-specific to the fear-conditioning paradigm.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
freezing levelsReported result 75 mg/kg; 4 days after injection; without any shock or tone delivery: an increase in freezing levels during the latter part of the behavioural sessions, referred to as ‘post-tone’ period, but not during the early ‘pre-tone’ period.[2]

Conditions shared by the study groups

Route
intraperitoneally
Treatment course
4 days after injection
Vehicle
sterile saline
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Methimazole 75 mg/kgan equivalent volume of saline75 mg/kg; 4 days after injection; without any shock or tone delivery: an increase in freezing levels during the latter part of the behavioural sessions, referred to as ‘post-tone’ period, but not during the early ‘pre-tone’ period.[2]
Methimazole 75 mg/kg
Model: Mice
Methods and source locations

Compound reported in the paper: Methimazole

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Results > 4 Hz rhythm is necessary for freezing expression (S59, S60); Methods > Methimazole injection and behavioural study (S194, S198)

freezing levels: freezing levels; comparator: an equivalent volume of saline — Results > 4 Hz rhythm is necessary for freezing expression (S59, S60); Methods > Methimazole injection and behavioural study (S194, S198)

Methimazole 75 mg/kg · Results > 4 Hz rhythm is necessary for freezing expression (S59, S60); Methods > Methimazole injection and behavioural study (S194, S198)

Methimazole and Weight Loss in Mice

Animal study · Mice [2]

Mice received Methimazole intraperitoneally and were weighed daily after injection. Substantial weight loss was observed.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
weighed dailyReported result 75 mg/kg: substantial weight loss.[2]

Conditions shared by the study groups

Route
intraperitoneally
Treatment course
After injection, mice were weighed daily
Vehicle
sterile saline
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Methimazole 75 mg/kgan equivalent volume of saline75 mg/kg: substantial weight loss.[2]
Methimazole 75 mg/kg
Model: Mice
Methods and source locations

Compound reported in the paper: Methimazole

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Results > 4 Hz rhythm is necessary for freezing expression (S54); Methods > Methimazole injection and behavioural study (S194, S195)

weighed daily: weighed daily; comparator: an equivalent volume of saline — Results > 4 Hz rhythm is necessary for freezing expression (S54); Methods > Methimazole injection and behavioural study (S194, S195)

Methimazole 75 mg/kg · Results > 4 Hz rhythm is necessary for freezing expression (S54); Methods > Methimazole injection and behavioural study (S194, S195)

Specifications

Manufacturer Adooq Bioscience
CAS Number 60-56-0
Applications Anti-thyroid Agent
Formula C4H6N2S
Molecular Weight 114.17
Synonyms Thiamazole
SMILES
S=C1NC=CN1C

Storage & Solubility

In Vitro Solubility

Reported Solubility

No reported solubility data are available for this product.

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Research References

  1. [1] Michaud V, Frappier M, Dumas MC, et al. Metabolic activity and mRNA levels of human cardiac CYP450s involved in drug metabolism. PLoS One (2010). PMID: 21179487 DOI: 10.1371/journal.pone.0015666 Source material
  2. [2] Bagur S, Lefort JM, Lacroix MM, et al. Breathing-driven prefrontal oscillations regulate maintenance of conditioned-fear evoked freezing independently of initiation. Nat Commun (2021). PMID: 33972521 DOI: 10.1038/s41467-021-22798-6 Source material

Added to your cart

View Cart Checkout
Loading...